Atacand (Candesartan) Real Life Study

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a Swedish historical cohort study in patients prescribed Atacand or Cozaar for hypertension by selected primary care centres. Data will be extracted anonymously from electronic medical records. In addition, data regarding morbidity and mortality will be collected by merging the cohort with the following national registries: the Hospital Discharge Register (Slutenvårdsregistret), the Cause of Death Register and the Heart Intensive Care Admission (RIKS-HIA)

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Candesartan; Candesartan cilexetil; Losartan

Criteria

Inclusion Criteria:

• Recorded blood pressure prior to therapy of > 140 and/or 90 mmHg

• Diagnosed as hypertensive within 15 months

• First prescription of Cozaar or Atacand between 1 January 1999 and 31 December 2007, inclusive

Exclusion Criteria:

• Previous prescription within 15 months any drug from the ATC groups C02, C03, C07 - C09 inclusive